Bio-Rad Laboratories, Inc. reports news on its life science research and clinical diagnostics products, including instruments, reagents, test systems, specialized quality controls, blood typing, diabetes products, infectious disease products, and Droplet Digital PCR technologies.
Company updates commonly cover quarterly and annual financial results, Clinical Diagnostics and Life Science segment trends, currency and end-market conditions, product portfolio developments, share repurchases, earnings calls, and healthcare investor conferences. Bio-Rad’s customer base includes universities, research institutions, hospitals, biopharmaceutical companies, and clinical, food safety, and environmental quality laboratories.
Bio-Rad Laboratories (BIO) reported third-quarter 2026 sales of $656.4 million, with growth in Clinical Diagnostics offsetting a decline in Life Science. Sales rose 0.5% year over year, or 0.7% excluding currency effects. Clinical Diagnostics sales increased 2.7% to $401.8 million; Life Science sales fell 2.8% to $254.6 million.
The GAAP operating result swung to a $49.7 million loss from $65.3 million income. Net income reached $458.6 million, or $17.02 per diluted share, substantially helped by the change in value of the Sartorius investment. Non-GAAP diluted earnings rose to $2.65 from $2.26. Operating cash flow fell to $96.4 million from $120.9 million.
Bio-Rad maintained its full-year outlook for non-GAAP, currency-neutral revenue ranging from an approximately 3.0% decline to approximately 0.5% growth, with an estimated non-GAAP operating margin of approximately 10.0% to 12.0%.
Bio-Rad Laboratories (NYSE: BIO and BIO.B) will participate in a fireside chat at the UBS Global Healthcare Conference on November 10, 2026.
Chief Financial Officer Roop K. Lakkaraju will participate at 8:00 AM Eastern Time. A live webcast and subsequent replay will be available in the Investor Relations section at investors.bio-rad.com.
Bio-Rad Laboratories (BIO) will report third-quarter 2026 financial results after the market closes on November 4, 2026.
Management will discuss the results on a conference call at 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. A live webcast will be available at investors.bio-rad.com under Investor Relations, Events & Presentations, with a replay available for up to a year.
Bio-Rad (BIO)/b) will participate in a fireside chat at the Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum on Thursday, September 24, 2026, at 8:50 AM Eastern Time.A live webcast and a replay of the event will be available in the Investor Relations section of Bio-Rad’s website at investors.bio-rad.com.
Bio-Rad (NYSE: BIO, BIO.B) announced that Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat at Wells Fargo’s 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 3:45 PM ET (12:45 PM PT). A live webcast and replay will be accessible via the Investor Relations section of Bio-Rad’s website at investors.bio-rad.com.
Insight Molecular Diagnostics (Nasdaq: IMDX) reported Q2 2026 revenue of approximately $239,000, largely from laboratory services, plus $21,000 from research-use-only kits, and gross profit of $157,000, a 65.7% gross margin. Net loss was $11.3 million, or $0.31 per share, and adjusted net loss was $8.3 million, or $0.23 per share.
Operating expenses were $11.6 million, including $2.3 million non-cash contingent consideration, $661,000 stock-based compensation, and $641,000 depreciation and amortization. Non-GAAP operating expenses decreased 13% sequentially but rose 26% year over year. Adjusted EBITDA loss was $7.8 million. IMDX ended Q2 with $18.7 million in cash, cash equivalents and restricted cash and outgoing free cash flow of about $10 million.
The company highlighted timely FDA review progress for its GraftAssureDx kidney transplant test kit, favorable Medicare reimbursement changes for dd-cfDNA surveillance and treatment-response monitoring, and multiple peer-reviewed clinical studies showing strong performance and head-to-head analytical data for GraftAssure.
Bio-Rad (NYSE: BIO) reported Q2 2026 net sales of $651.0 million, essentially flat versus Q2 2025’s $651.6 million; currency-neutral sales declined 1.9%, driven by lower Life Science revenue. GAAP gross margin was 53.1% and non-GAAP gross margin 53.9%.
Life Science segment sales were $252.0 million, down 4.1% (5.1% currency-neutral), while Clinical Diagnostics sales were $399.0 million, up 2.6% (0.3% currency-neutral). GAAP income from operations was $72.6 million versus $77.1 million a year ago.
Helped largely by a change in the fair value of its Sartorius AG investment, Bio-Rad reported Q2 GAAP net income of $371.4 million or $13.85 per diluted share. Non-GAAP net income was $70.2 million or $2.62 per diluted share. Operating cash flow was $98.7 million, and the company repurchased about $32 million of shares. For full-year 2026, Bio-Rad reaffirmed guidance for non-GAAP, currency-neutral revenue ranging from a 3.0% decline to 0.5% growth and a non-GAAP operating margin of 10.0–12.0%, according to the company.
Bio-Rad (NYSE: BIO, BIO.B) announced it will report its second-quarter 2026 financial results on Tuesday, August 4, 2026, after the market close. Company management will host a conference call at 2:00 PM Pacific Time (5:00 PM Eastern Time) the same day to discuss the results.
Investors can join the call by dialing (800) 715-9871 in the U.S. or (646) 307-1963 internationally, with access code 9562470. A live webcast will be available in the Investor Relations > Events & Presentations section at investors.bio-rad.com, and a replay of the webcast will remain accessible for up to one year.
Bio-Rad (NYSE: BIO) will participate in two investor conferences in May–June 2026, with CFO Roop K. Lakkaraju hosting fireside chats and one-on-one investor meetings.
Events: RBC Capital Markets Global Healthcare Conference on May 19, 2026 at 8:30 AM ET, and Jefferies Global Healthcare Conference on June 3, 2026 at 8:45 AM ET. Live webcasts and replays will be available in the Investor Relations section at bio-rad.com.
Bio-Rad (NYSE: BIO) reported Q1 2026 results: net sales $592.1M (+1.1% YoY; currency-neutral -4.2%). GAAP net loss was $527.1M due to a fair-value change in a Sartorius AG investment; non-GAAP net income was $50.9M and free cash flow was $78.1M. The company updated 2026 non-GAAP guidance to currency-neutral revenue -3.0% to +0.5% and estimated non-GAAP operating margin ~10.0–12.0%.